Anzeige
Mehr »
Login
Samstag, 28.11.2020 Börsentäglich über 12.000 News von 646 internationalen Medien
Diese Firma ist einfach nicht zu stoppen! Top-News am laufenden Band!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12HVG ISIN: US71715X1046 Ticker-Symbol: EFY 
Stuttgart
27.11.20
07:13 Uhr
0,005 Euro
0,000
0,00 %
1-Jahres-Chart
PHARMACYTE BIOTECH INC Chart 1 Jahr
5-Tage-Chart
PHARMACYTE BIOTECH INC 5-Tage-Chart

Aktuelle News zur PHARMACYTE Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PHARMACYTE Aktie jetzt für 0€ handeln
04.11.PharmaCyte Biotech's Investigational New Drug Application Placed on Hold by the FDA8
16.10.PharmaCyte Biotech, Inc. - 8-K, Current Report8
02.10.FDA places hold on PharmaCyte's cell therapy IND for pancreatic cancer6
11.09.PharmaCyte Biotech, Inc. - 10-Q, Quaterly Report10
03.09.PharmaCyte Biotech submits IND to FDA for clinical trial in inoperable pancreatic cancer3
13.08.PharmaCyte Biotech, Inc. - 10-K, Annual Report7
03.08.PharmaCyte Biotech Ready to Submit Investigational New Drug Application to FDA for Clinical Trial in Pancreatic Cancer8
29.07.PharmaCyte Biotech, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT40510
29.07.PharmaCyte Biotech Receives CE Mark for Licensed COVID-19 Molecular Tests296PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box...
► Artikel lesen
29.06.PharmaCyte Biotech's COVID-19 Test Offers "Pool Testing" Dr. Fauci and White House Coronavirus Task Force Now Considering11
11.02.Will PharmaCyte Biotech's Cell-in-a-Box(R) Technology Be The Game Changer To Effectively Treating Pancreatic Cancer?427PCG Media covers the value that PharmaCyte's Cell-in-a-Box technology can bring to the pancreatic cancer market. Future indications expected to target diabetes and cannabinoid therapy.New York, New...
► Artikel lesen
06.02.PharmaCyte Biotech Exploits Potential Of Its Cell-in-a-Box(R) Technology; Targets Billion Dollar Cancer, Diabetes, and Medicinal Cannabinoid Markets385Soulstring Media Group covers how this emerging biotech can become a potential leader in treating pancreatic cancer and diabetes with its Cell-in-a-Box(R) technologyMiami Beach, Florida--(Newsfile Corp....
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1